Why deny ACE inhibitors to patients with aortic stenosis?

Lancet

Volumn 352, Issue 9122, 1998, Pages 111-112

  Cox, Niall L T ^a   Abdul Hamid, Ahmed R ^b   Mulley, Graham P ^b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AORTA STENOSIS; ARTICLE; DRUG CHOICE; HUMAN; HYPOTENSION; PRESCRIPTION; PRIORITY JOURNAL;

EID: 0032508295     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)85016-2     Document Type: Article

References (5)

1. Grose RG, Nivatpumin T, Katz S, Yipintosi T, Scheur J. Mechanism of nitroglycerin effect in valvular aortic stenosis. Am J Cardiol 1979; 44: 1371-77.
2. Awan NA, DeMaria AN, Miller RR, Amsterdam EA, Mason DT. Beneficial effects of nitroprusside administration on left ventricular dysfunction and myocardial ischaemia in severe aortic stenosis. Am Heart J 1981; 101: 386-88.
3. Riegger GA, Wolf P, Kochsiek K. Vasoconstrictor role of vasopressin and angiotensin in experimental aortic stenosis in the rat. J Cardiovas Pharmacol 1988; 11: 538-42.
4. Wong SS, Long CC, Holt PJ. Lichenoid eruption induced by low-dose captopril. Acta Derm Venereol 1992; 72: 357-59.
5. McGrath BP, Denham IM, Johnston CI. Clinical improvement and hormonal changes in severe cardiac failure after captopril treatment. Aust NZ J Med 1981; 11: 639-44.